Drugs / Vosaroxin
Vosaroxin
Trials 16 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02272478 Comparator | Oct 2014 → Feb 2021 | acute myeloid leukemia, myelodysplastic syndrome | Cardiff University | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vosaroxin | “Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II.” PMID 25381131 ↗ Nov 2014 |
| Known as | AG-7352 | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | SNS-595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00252382 ↗ |
| Known as | SPC-595 | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | Voreloxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00541866 ↗ |
| Known as | Vosaroxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Known as | Vosaroxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL68117 ↗ |
| Action | Inhibit | “inhibiting topoisomerase II” NCT00252382 ↗ |
| Modality | Small molecule | “a first in class anticancer quinolone derivative” NCT00252382 ↗ |
| Route | Intravenous | “SNS-595 given intravenously once every 3 weeks” NCT00091585 ↗ |